Repairing neurological damage caused by stroke, Parkinson’s disease and other brain conditions isn’t all fun and games, but digital therapeutics developers like MindMaze are aiming to bring a bit of levity to what can otherwise be a difficult and stressful process.
Roche’s Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene’s gene therapy for epilepsy, which has a specific focus on drug-resistant forms of the condition.
Axial Therapeutics has picked up $37.3 million to bankroll a midstage test in autism and fund further work on neurological diseases.
BioNova Pharmaceuticals has a couple molecules in early development for blood cancers, but, in an effort to get to the clinic faster, the biotech is doling out $200 million to Sutro Biopharma for some more advanced treatments.
The Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a co-founder of C4 Therapeutics.
Takeda’s fervor for gene therapies hit a new peak Tuesday in a research collaboration that could skyrocket to $3.6 billion for Poseida Therapeutics.
Almost a year to the day after Gossamer Bio’s lead program failed twice in phase 2, the California biotech is unveiling two preclinical assets ready to enter the clinic in an effort to turn things around.
Protalix reaches agreement with FDA on Fabry data package, but resubmission of PRX–102 could be years out
Protalix BioTherapeutics has found a path forward for resubmitting an application for a Fabry disease medicine with the FDA; it’s just going to take a while.
A month ago, Protagonist Therapeutics’ shares more than halved on an FDA clinical hold of its blood cancer drug after worrying preclinical safety signals.
Idorsia’s Fabry med did what executives were expecting—it just didn’t relieve the disease’s hallmark burning pain
Idorsia’s Fabry disease therapy “did exactly what we were expecting,” according to one executive—except relieve neuropathic pain.